Global Choroidal Neovascularization Drug market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031. Get Access Now!

Global Choroidal Neovascularization Drug Market Size and Outlook 2025-31

The global Choroidal Neovascularization Drug market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031. The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs. Infinity Market Research newest research report, the Choroidal Neovascularization Drug Industry Forecast looks at past sales and reviews total world Choroidal Neovascularization Drug sales in 2024, providing a comprehensive analysis by region and market sector of projected Choroidal Neovascularization Drug sales for 2025 through 2031. With Choroidal Neovascularization Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Choroidal Neovascularization Drug industry. This Insight Report provides a comprehensive analysis of the global Choroidal Neovascularization Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Choroidal Neovascularization Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms unique position in an accelerating global Choroidal Neovascularization Drug market. This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Choroidal Neovascularization Drug and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Choroidal Neovascularization Drug. This report presents a comprehensive overview, market shares, and growth opportunities of Choroidal Neovascularization Drug market by product type, application, key manufacturers and key regions and countries. Segmentation by Type: &nbsp;&nbsp;&nbsp; AVMOC-001 &nbsp;&nbsp;&nbsp; BB-3 &nbsp;&nbsp;&nbsp; BBT-007 &nbsp;&nbsp;&nbsp; DG-3 &nbsp;&nbsp;&nbsp; Entolimod &nbsp;&nbsp;&nbsp; EWA-001 &nbsp;&nbsp;&nbsp; Others Segmentation by Application: &nbsp;&nbsp;&nbsp; Clinic &nbsp;&nbsp;&nbsp; Hospital &nbsp;&nbsp;&nbsp; Others This report also splits the market by region: &nbsp;&nbsp;&nbsp; Americas &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; United States &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Canada &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mexico &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Brazil &nbsp;&nbsp;&nbsp; APAC &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; China &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Japan &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Korea &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Southeast Asia &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; India &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Australia &nbsp;&nbsp;&nbsp; Europe &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Germany &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; France &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; UK &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Italy &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Russia &nbsp;&nbsp;&nbsp; Middle East & Africa &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Egypt &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; South Africa &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Israel &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Turkey &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; GCC Countries The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the companys coverage, product portfolio, its market penetration. &nbsp;&nbsp;&nbsp; Cellphire, Inc. &nbsp;&nbsp;&nbsp; Chrysalis BioTherapeutics, Inc. &nbsp;&nbsp;&nbsp; Cleveland BioLabs, Inc. &nbsp;&nbsp;&nbsp; Cumberland Pharmaceuticals, Inc. &nbsp;&nbsp;&nbsp; Diffusion Pharmaceuticals Inc. &nbsp;&nbsp;&nbsp; Eli Lilly and Company &nbsp;&nbsp;&nbsp; GNI Group Ltd. &nbsp;&nbsp;&nbsp; Humanetics Corporation &nbsp;&nbsp;&nbsp; INSYS Therapeutics, Inc. &nbsp;&nbsp;&nbsp; Meabco A/S &nbsp;&nbsp;&nbsp; Neumedicines Inc. &nbsp;&nbsp;&nbsp; Onconova Therapeutics, Inc. &nbsp;&nbsp;&nbsp; PharmaIN Corporation &nbsp;&nbsp;&nbsp; Pluristem Therapeutics Inc. &nbsp;&nbsp;&nbsp; ProCertus BioPharm Inc. &nbsp;&nbsp;&nbsp; RDD Pharma Ltd. &nbsp;&nbsp;&nbsp; RedHill Biopharma Ltd. &nbsp;&nbsp;&nbsp; RxBio, Inc. &nbsp;&nbsp;&nbsp; Soligenix, Inc. Key Questions Addressed in this Report What is the 10-year outlook for the global Choroidal Neovascularization Drug market? What factors are driving Choroidal Neovascularization Drug market growth, globally and by region? Which technologies are poised for the fastest growth by market and region? How do Choroidal Neovascularization Drug market opportunities vary by end market size? How does Choroidal Neovascularization Drug break out by Type, by Application?

1 Scope of the Report &nbsp;1.1 Market Introduction &nbsp;1.2 Years Considered &nbsp;1.3 Research Objectives &nbsp;1.4 Market Research Methodology &nbsp;1.5 Research Process and Data Source &nbsp;1.6 Economic Indicators &nbsp;1.7 Currency Considered &nbsp;1.8 Market Estimation Caveats 2 Executive Summary &nbsp;2.1 World Market Overview &nbsp;2.1.1 Global Choroidal Neovascularization Drug Annual Sales 2020-2031 &nbsp;2.1.2 World Current & Future Analysis for Choroidal Neovascularization Drug by Geographic Region, 2020, 2024 & 2031 &nbsp;2.1.3 World Current & Future Analysis for Choroidal Neovascularization Drug by Country/Region, 2020, 2024 & 2031 &nbsp;2.2 Choroidal Neovascularization Drug Segment by Type &nbsp;2.2.1 AVMOC-001 &nbsp;2.2.2 BB-3 &nbsp;2.2.3 BBT-007 &nbsp;2.2.4 DG-3 &nbsp;2.2.5 Entolimod &nbsp;2.2.6 EWA-001 &nbsp;2.2.7 Others &nbsp;2.3 Choroidal Neovascularization Drug Sales by Type &nbsp;2.3.1 Global Choroidal Neovascularization Drug Sales Market Share by Type (2020-2025) &nbsp;2.3.2 Global Choroidal Neovascularization Drug Revenue and Market Share by Type (2020-2025) &nbsp;2.3.3 Global Choroidal Neovascularization Drug Sale Price by Type (2020-2025) &nbsp;2.4 Choroidal Neovascularization Drug Segment by Application &nbsp;2.4.1 Clinic &nbsp;2.4.2 Hospital &nbsp;2.4.3 Others &nbsp;2.5 Choroidal Neovascularization Drug Sales by Application &nbsp;2.5.1 Global Choroidal Neovascularization Drug Sale Market Share by Application (2020-2025) &nbsp;2.5.2 Global Choroidal Neovascularization Drug Revenue and Market Share by Application (2020-2025) &nbsp;2.5.3 Global Choroidal Neovascularization Drug Sale Price by Application (2020-2025) 3 Global by Company &nbsp;3.1 Global Choroidal Neovascularization Drug Breakdown Data by Company &nbsp;3.1.1 Global Choroidal Neovascularization Drug Annual Sales by Company (2020-2025) &nbsp;3.1.2 Global Choroidal Neovascularization Drug Sales Market Share by Company (2020-2025) &nbsp;3.2 Global Choroidal Neovascularization Drug Annual Revenue by Company (2020-2025) &nbsp;3.2.1 Global Choroidal Neovascularization Drug Revenue by Company (2020-2025) &nbsp;3.2.2 Global Choroidal Neovascularization Drug Revenue Market Share by Company (2020-2025) &nbsp;3.3 Global Choroidal Neovascularization Drug Sale Price by Company &nbsp;3.4 Key Manufacturers Choroidal Neovascularization Drug Producing Area Distribution, Sales Area, Product Type &nbsp;3.4.1 Key Manufacturers Choroidal Neovascularization Drug Product Location Distribution &nbsp;3.4.2 Players Choroidal Neovascularization Drug Products Offered &nbsp;3.5 Market Concentration Rate Analysis &nbsp;3.5.1 Competition Landscape Analysis &nbsp;3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025) &nbsp;3.6 New Products and Potential Entrants &nbsp;3.7 Market M&A Activity & Strategy 4 World Historic Review for Choroidal Neovascularization Drug by Geographic Region &nbsp;4.1 World Historic Choroidal Neovascularization Drug Market Size by Geographic Region (2020-2025) &nbsp;4.1.1 Global Choroidal Neovascularization Drug Annual Sales by Geographic Region (2020-2025) &nbsp;4.1.2 Global Choroidal Neovascularization Drug Annual Revenue by Geographic Region (2020-2025) &nbsp;4.2 World Historic Choroidal Neovascularization Drug Market Size by Country/Region (2020-2025) &nbsp;4.2.1 Global Choroidal Neovascularization Drug Annual Sales by Country/Region (2020-2025) &nbsp;4.2.2 Global Choroidal Neovascularization Drug Annual Revenue by Country/Region (2020-2025) &nbsp;4.3 Americas Choroidal Neovascularization Drug Sales Growth &nbsp;4.4 APAC Choroidal Neovascularization Drug Sales Growth &nbsp;4.5 Europe Choroidal Neovascularization Drug Sales Growth &nbsp;4.6 Middle East & Africa Choroidal Neovascularization Drug Sales Growth 5 Americas &nbsp;5.1 Americas Choroidal Neovascularization Drug Sales by Country &nbsp;5.1.1 Americas Choroidal Neovascularization Drug Sales by Country (2020-2025) &nbsp;5.1.2 Americas Choroidal Neovascularization Drug Revenue by Country (2020-2025) &nbsp;5.2 Americas Choroidal Neovascularization Drug Sales by Type (2020-2025) &nbsp;5.3 Americas Choroidal Neovascularization Drug Sales by Application (2020-2025) &nbsp;5.4 United States &nbsp;5.5 Canada &nbsp;5.6 Mexico &nbsp;5.7 Brazil 6 APAC &nbsp;6.1 APAC Choroidal Neovascularization Drug Sales by Region &nbsp;6.1.1 APAC Choroidal Neovascularization Drug Sales by Region (2020-2025) &nbsp;6.1.2 APAC Choroidal Neovascularization Drug Revenue by Region (2020-2025) &nbsp;6.2 APAC Choroidal Neovascularization Drug Sales by Type (2020-2025) &nbsp;6.3 APAC Choroidal Neovascularization Drug Sales by Application (2020-2025) &nbsp;6.4 China &nbsp;6.5 Japan &nbsp;6.6 South Korea &nbsp;6.7 Southeast Asia &nbsp;6.8 India &nbsp;6.9 Australia &nbsp;6.10 China Taiwan 7 Europe &nbsp;7.1 Europe Choroidal Neovascularization Drug by Country &nbsp;7.1.1 Europe Choroidal Neovascularization Drug Sales by Country (2020-2025) &nbsp;7.1.2 Europe Choroidal Neovascularization Drug Revenue by Country (2020-2025) &nbsp;7.2 Europe Choroidal Neovascularization Drug Sales by Type (2020-2025) &nbsp;7.3 Europe Choroidal Neovascularization Drug Sales by Application (2020-2025) &nbsp;7.4 Germany &nbsp;7.5 France &nbsp;7.6 UK &nbsp;7.7 Italy &nbsp;7.8 Russia 8 Middle East & Africa &nbsp;8.1 Middle East & Africa Choroidal Neovascularization Drug by Country &nbsp;8.1.1 Middle East & Africa Choroidal Neovascularization Drug Sales by Country (2020-2025) &nbsp;8.1.2 Middle East & Africa Choroidal Neovascularization Drug Revenue by Country (2020-2025) &nbsp;8.2 Middle East & Africa Choroidal Neovascularization Drug Sales by Type (2020-2025) &nbsp;8.3 Middle East & Africa Choroidal Neovascularization Drug Sales by Application (2020-2025) &nbsp;8.4 Egypt &nbsp;8.5 South Africa &nbsp;8.6 Israel &nbsp;8.7 Turkey &nbsp;8.8 GCC Countries 9 Market Drivers, Challenges and Trends &nbsp;9.1 Market Drivers & Growth Opportunities &nbsp;9.2 Market Challenges & Risks &nbsp;9.3 Industry Trends 10 Manufacturing Cost Structure Analysis &nbsp;10.1 Raw Material and Suppliers &nbsp;10.2 Manufacturing Cost Structure Analysis of Choroidal Neovascularization Drug &nbsp;10.3 Manufacturing Process Analysis of Choroidal Neovascularization Drug &nbsp;10.4 Industry Chain Structure of Choroidal Neovascularization Drug 11 Marketing, Distributors and Customer &nbsp;11.1 Sales Channel &nbsp;11.1.1 Direct Channels &nbsp;11.1.2 Indirect Channels &nbsp;11.2 Choroidal Neovascularization Drug Distributors &nbsp;11.3 Choroidal Neovascularization Drug Customer 12 World Forecast Review for Choroidal Neovascularization Drug by Geographic Region &nbsp;12.1 Global Choroidal Neovascularization Drug Market Size Forecast by Region &nbsp;12.1.1 Global Choroidal Neovascularization Drug Forecast by Region (2026-2031) &nbsp;12.1.2 Global Choroidal Neovascularization Drug Annual Revenue Forecast by Region (2026-2031) &nbsp;12.2 Americas Forecast by Country (2026-2031) &nbsp;12.3 APAC Forecast by Region (2026-2031) &nbsp;12.4 Europe Forecast by Country (2026-2031) &nbsp;12.5 Middle East & Africa Forecast by Country (2026-2031) &nbsp;12.6 Global Choroidal Neovascularization Drug Forecast by Type (2026-2031) &nbsp;12.7 Global Choroidal Neovascularization Drug Forecast by Application (2026-2031) 13 Key Players Analysis &nbsp;13.1 Cellphire, Inc. &nbsp;13.1.1 Cellphire, Inc. Company Information &nbsp;13.1.2 Cellphire, Inc. Choroidal Neovascularization Drug Product Portfolios and Specifications &nbsp;13.1.3 Cellphire, Inc. Choroidal Neovascularization Drug Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.1.4 Cellphire, Inc. Main Business Overview &nbsp;13.1.5 Cellphire, Inc. Latest Developments &nbsp;13.2 Chrysalis BioTherapeutics, Inc. &nbsp;13.2.1 Chrysalis BioTherapeutics, Inc. Company Information &nbsp;13.2.2 Chrysalis BioTherapeutics, Inc. Choroidal Neovascularization Drug Product Portfolios and Specifications &nbsp;13.2.3 Chrysalis BioTherapeutics, Inc. Choroidal Neovascularization Drug Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.2.4 Chrysalis BioTherapeutics, Inc. Main Business Overview &nbsp;13.2.5 Chrysalis BioTherapeutics, Inc. Latest Developments &nbsp;13.3 Cleveland BioLabs, Inc. &nbsp;13.3.1 Cleveland BioLabs, Inc. Company Information &nbsp;13.3.2 Cleveland BioLabs, Inc. Choroidal Neovascularization Drug Product Portfolios and Specifications &nbsp;13.3.3 Cleveland BioLabs, Inc. Choroidal Neovascularization Drug Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.3.4 Cleveland BioLabs, Inc. Main Business Overview &nbsp;13.3.5 Cleveland BioLabs, Inc. Latest Developments &nbsp;13.4 Cumberland Pharmaceuticals, Inc. &nbsp;13.4.1 Cumberland Pharmaceuticals, Inc. Company Information &nbsp;13.4.2 Cumberland Pharmaceuticals, Inc. Choroidal Neovascularization Drug Product Portfolios and Specifications &nbsp;13.4.3 Cumberland Pharmaceuticals, Inc. Choroidal Neovascularization Drug Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.4.4 Cumberland Pharmaceuticals, Inc. Main Business Overview &nbsp;13.4.5 Cumberland Pharmaceuticals, Inc. Latest Developments &nbsp;13.5 Diffusion Pharmaceuticals Inc. &nbsp;13.5.1 Diffusion Pharmaceuticals Inc. Company Information &nbsp;13.5.2 Diffusion Pharmaceuticals Inc. Choroidal Neovascularization Drug Product Portfolios and Specifications &nbsp;13.5.3 Diffusion Pharmaceuticals Inc. Choroidal Neovascularization Drug Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.5.4 Diffusion Pharmaceuticals Inc. Main Business Overview &nbsp;13.5.5 Diffusion Pharmaceuticals Inc. Latest Developments &nbsp;13.6 Eli Lilly and Company &nbsp;13.6.1 Eli Lilly and Company Company Information &nbsp;13.6.2 Eli Lilly and Company Choroidal Neovascularization Drug Product Portfolios and Specifications &nbsp;13.6.3 Eli Lilly and Company Choroidal Neovascularization Drug Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.6.4 Eli Lilly and Company Main Business Overview &nbsp;13.6.5 Eli Lilly and Company Latest Developments &nbsp;13.7 GNI Group Ltd. &nbsp;13.7.1 GNI Group Ltd. Company Information &nbsp;13.7.2 GNI Group Ltd. Choroidal Neovascularization Drug Product Portfolios and Specifications &nbsp;13.7.3 GNI Group Ltd. Choroidal Neovascularization Drug Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.7.4 GNI Group Ltd. Main Business Overview &nbsp;13.7.5 GNI Group Ltd. Latest Developments &nbsp;13.8 Humanetics Corporation &nbsp;13.8.1 Humanetics Corporation Company Information &nbsp;13.8.2 Humanetics Corporation Choroidal Neovascularization Drug Product Portfolios and Specifications &nbsp;13.8.3 Humanetics Corporation Choroidal Neovascularization Drug Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.8.4 Humanetics Corporation Main Business Overview &nbsp;13.8.5 Humanetics Corporation Latest Developments &nbsp;13.9 INSYS Therapeutics, Inc. &nbsp;13.9.1 INSYS Therapeutics, Inc. Company Information &nbsp;13.9.2 INSYS Therapeutics, Inc. Choroidal Neovascularization Drug Product Portfolios and Specifications &nbsp;13.9.3 INSYS Therapeutics, Inc. Choroidal Neovascularization Drug Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.9.4 INSYS Therapeutics, Inc. Main Business Overview &nbsp;13.9.5 INSYS Therapeutics, Inc. Latest Developments &nbsp;13.10 Meabco A/S &nbsp;13.10.1 Meabco A/S Company Information &nbsp;13.10.2 Meabco A/S Choroidal Neovascularization Drug Product Portfolios and Specifications &nbsp;13.10.3 Meabco A/S Choroidal Neovascularization Drug Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.10.4 Meabco A/S Main Business Overview &nbsp;13.10.5 Meabco A/S Latest Developments &nbsp;13.11 Neumedicines Inc. &nbsp;13.11.1 Neumedicines Inc. Company Information &nbsp;13.11.2 Neumedicines Inc. Choroidal Neovascularization Drug Product Portfolios and Specifications &nbsp;13.11.3 Neumedicines Inc. Choroidal Neovascularization Drug Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.11.4 Neumedicines Inc. Main Business Overview &nbsp;13.11.5 Neumedicines Inc. Latest Developments &nbsp;13.12 Onconova Therapeutics, Inc. &nbsp;13.12.1 Onconova Therapeutics, Inc. Company Information &nbsp;13.12.2 Onconova Therapeutics, Inc. Choroidal Neovascularization Drug Product Portfolios and Specifications &nbsp;13.12.3 Onconova Therapeutics, Inc. Choroidal Neovascularization Drug Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.12.4 Onconova Therapeutics, Inc. Main Business Overview &nbsp;13.12.5 Onconova Therapeutics, Inc. Latest Developments &nbsp;13.13 PharmaIN Corporation &nbsp;13.13.1 PharmaIN Corporation Company Information &nbsp;13.13.2 PharmaIN Corporation Choroidal Neovascularization Drug Product Portfolios and Specifications &nbsp;13.13.3 PharmaIN Corporation Choroidal Neovascularization Drug Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.13.4 PharmaIN Corporation Main Business Overview &nbsp;13.13.5 PharmaIN Corporation Latest Developments &nbsp;13.14 Pluristem Therapeutics Inc. &nbsp;13.14.1 Pluristem Therapeutics Inc. Company Information &nbsp;13.14.2 Pluristem Therapeutics Inc. Choroidal Neovascularization Drug Product Portfolios and Specifications &nbsp;13.14.3 Pluristem Therapeutics Inc. Choroidal Neovascularization Drug Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.14.4 Pluristem Therapeutics Inc. Main Business Overview &nbsp;13.14.5 Pluristem Therapeutics Inc. Latest Developments &nbsp;13.15 ProCertus BioPharm Inc. &nbsp;13.15.1 ProCertus BioPharm Inc. Company Information &nbsp;13.15.2 ProCertus BioPharm Inc. Choroidal Neovascularization Drug Product Portfolios and Specifications &nbsp;13.15.3 ProCertus BioPharm Inc. Choroidal Neovascularization Drug Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.15.4 ProCertus BioPharm Inc. Main Business Overview &nbsp;13.15.5 ProCertus BioPharm Inc. Latest Developments &nbsp;13.16 RDD Pharma Ltd. &nbsp;13.16.1 RDD Pharma Ltd. Company Information &nbsp;13.16.2 RDD Pharma Ltd. Choroidal Neovascularization Drug Product Portfolios and Specifications &nbsp;13.16.3 RDD Pharma Ltd. Choroidal Neovascularization Drug Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.16.4 RDD Pharma Ltd. Main Business Overview &nbsp;13.16.5 RDD Pharma Ltd. Latest Developments &nbsp;13.17 RedHill Biopharma Ltd. &nbsp;13.17.1 RedHill Biopharma Ltd. Company Information &nbsp;13.17.2 RedHill Biopharma Ltd. Choroidal Neovascularization Drug Product Portfolios and Specifications &nbsp;13.17.3 RedHill Biopharma Ltd. Choroidal Neovascularization Drug Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.17.4 RedHill Biopharma Ltd. Main Business Overview &nbsp;13.17.5 RedHill Biopharma Ltd. Latest Developments &nbsp;13.18 RxBio, Inc. &nbsp;13.18.1 RxBio, Inc. Company Information &nbsp;13.18.2 RxBio, Inc. Choroidal Neovascularization Drug Product Portfolios and Specifications &nbsp;13.18.3 RxBio, Inc. Choroidal Neovascularization Drug Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.18.4 RxBio, Inc. Main Business Overview &nbsp;13.18.5 RxBio, Inc. Latest Developments &nbsp;13.19 Soligenix, Inc. &nbsp;13.19.1 Soligenix, Inc. Company Information &nbsp;13.19.2 Soligenix, Inc. Choroidal Neovascularization Drug Product Portfolios and Specifications &nbsp;13.19.3 Soligenix, Inc. Choroidal Neovascularization Drug Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.19.4 Soligenix, Inc. Main Business Overview &nbsp;13.19.5 Soligenix, Inc. Latest Developments 14 Research Findings and Conclusion

Report	Global Choroidal Neovascularization Drug Market Growth 2025-2031
Selected License	Multi ID: LPI23911

Buyer Information

Order Summary